MedTrace Logo

Application of a TBE-Vaccine in Obese Persons

NCT04017052 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 73

Last updated 2019-09-10

No results posted yet for this study

Summary

Obese people have an altered immune responsiveness. The present study investigates whether this influences immune responses to booster vaccinations (i. e. booster vaccination with TBE vaccine "FSME Immun") and if a modification of vaccination schedules is needed.

Obese adults (BMI \>30) \>18 - 60 years are compared with adults with normal weight (BMI \<25) concerning TBE-NT- antibody titers, TBE- NT antibody titer course and cellular immunity. Metabolic parameters and sexual hormones will be tested and compared as well.

Conditions

  • Tick Borne Encephalitis

Interventions

DRUG

FSME-IMMUN Vaccine

Booster with TBE vaccine (i.m.) FSME Immun

Sponsors & Collaborators

  • Medical University of Vienna

    lead OTHER

Principal Investigators

  • Ursula Wiedermann-Schmidt, MD, PhD · Medical University of Vienna , ISPTM

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-04-15
Primary Completion
2020-02-07
Completion
2020-12-30

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04017052 on ClinicalTrials.gov